Specialized Commissioning Clinical Commissioning Policies Work Programme updated

On February 24, 2021, NHS England published an update of the Specialized Services Policy Pipeline (covering period November 10, 2020 - February 10, 2021).

Three types of Work Programmes exist:

• Clinical commissioning policy work program;
• Specialized commissioning service specification work program;
• Commissioning-through-Evaluation work programs.

Updates were only made in the clinical commissioning policy work program. Two new Clinical Commissioning Policies were added to the work program; however, only one related to med-tech (surgery for pectus deformity in all ages).

Seven new policies were published, five of which concern med-tech:

• Pharmacogenomic testing for DPYD polymorphisms with fluoropyrimidine therapies (published on November 25, 2020) is recommended to be available through routine commissioning as a pre-treatment screening test prior to the administration of fluoropyrimidine-based therapy;
• Stereotactic ablative radiotherapy (SABR) for patients with previously irradiated, locally recurrent primary pelvic tumours (all ages) (published on January 22, 2021) is recommended to be available as a treatment option through routine commissioning;
• Stereotactic ablative radiotherapy (SABR) for patients with previously irradiated, locally recurrent para-aortic tumours (all ages) (published on January 22, 2021) is not recommended to be available as a treatment option through routine commissioning;
• Stereotactic radiosurgery (SRS) and stereotactic radiotherapy (SRT) to the surgical cavity following resection of cerebral metastases (all ages) (published on January 22, 2021) is not recommended to be available as a treatment option through routine commissioning;
• Proton Beam Radiotherapy for Adult Primary Lung Cancer (published on February 11, 2021) is not recommended as a treatment option.

See the full details in English here.

This news is just one of about 300 market access news collected by our team in the subscription services "HTA Alerts" and "Reimbursement Alerts" every two weeks from more than 80 organizations. Access our paid subscription services to stay on top of all developments specifically for your products in Europe (reimbursement news) and globally (HTA news). First EU issues of both newsletters are available for download free-of-charge.

Not ready for a subscription service? Subscribe to our free-of-charge newsletter delivered every second week to get updates about key reimbursement developments in Europe (10-12 news every two weeks).